Left Ventricular Global Function Index: A Potential Predictor of Mortality and Major Adverse Cardiovascular Events in

Mesut Karatas1, Cengiz Sabanoglu2, Kader Eliz Sahin3

  • 1Department of Cardiology, Kosuyolu High Specialization Education and Research Hospital, Istanbul 34865, Turkey.

PubMed

Insights

The Left Ventricular Global Function Index (LVGFI) effectively predicts three-year mortality and major adverse cardiovascular events (MACE) in non-ST elevation myocardial infarction (NSTEMI) patients. Lower LVGFI indicates a significantly higher risk of adverse outcomes.

Area of Science:

  • Cardiology
  • Cardiovascular Imaging
  • Prognostic Biomarkers

Background:

  • The prognostic significance of Left Ventricular Global Function Index (LVGFI) is established in chronic cardiovascular diseases.
  • Limited data exists on LVGFI's predictive utility in non-ST elevation myocardial infarction (NSTEMI) patients.

Purpose of the Study:

  • To assess the Left Ventricular Global Function Index (LVGFI) as a predictor of three-year mortality.
  • To evaluate LVGFI's role in predicting major adverse cardiovascular events (MACE) in NSTEMI patients.

Main Methods:

  • Retrospective cohort study of 432 NSTEMI patients categorized into LVGFI tertiles (low, intermediate, high).
  • Echocardiographic LVGFI values analyzed using Kaplan-Meier survival and adjusted Cox proportional hazards models.
  • Outcomes assessed included three-year mortality and MACE.

Main Results:

  • An LVGFI cut-off of 23.22 predicted three-year mortality with 72% sensitivity and 75% specificity (AUC: 0.81).
  • The lowest LVGFI tertile (T1) showed a 25% three-year mortality rate versus 2.1% in the highest tertile (T3).
  • Adjusted analysis revealed significantly higher mortality (HR 11.86) and MACE rates in the lowest LVGFI tertile compared to the highest.

Conclusions:

  • Left Ventricular Global Function Index (LVGFI) is a significant independent predictor of adverse outcomes in NSTEMI.
  • LVGFI effectively stratifies risk for three-year mortality and MACE in this patient population.